Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)’s share price shot up 3.8% on Wednesday . The stock traded as high as $11.30 and last traded at $11.23, with a volume of 251,113 shares traded. The stock had previously closed at $10.82.

SCMP has been the subject of a number of analyst reports. WallachBeth Capital upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Thursday, May 5th. Mizuho restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. Guggenheim restated a “buy” rating and issued a $29.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. Maxim Group restated a “buy” rating and issued a $26.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Sunday, May 1st. Finally, Zacks Investment Research lowered shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 22nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and an average price target of $21.00.

The stock’s 50 day moving average is $11.34 and its 200 day moving average is $12.22. The company has a market capitalization of $486.83 million and a price-to-earnings ratio of 22.61.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.02. The business had revenue of $47.20 million for the quarter, compared to analysts’ expectations of $44.11 million. Sucampo Pharmaceuticals’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.14 EPS. Equities research analysts anticipate that Sucampo Pharmaceuticals Inc. will post $1.02 EPS for the current year.

Several large investors have added to or reduced their stakes in SCMP. Dimensional Fund Advisors LP raised its stake in Sucampo Pharmaceuticals by 7.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,532,411 shares of the biopharmaceutical company’s stock valued at $26,496,000 after buying an additional 106,463 shares during the last quarter. American Century Companies Inc. raised its stake in Sucampo Pharmaceuticals by 68.7% in the fourth quarter. American Century Companies Inc. now owns 401,691 shares of the biopharmaceutical company’s stock valued at $6,945,000 after buying an additional 163,558 shares during the last quarter. GSA Capital Partners LLP raised its stake in Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock valued at $3,802,000 after buying an additional 17,172 shares during the last quarter. Systematic Financial Management LP raised its stake in Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock valued at $1,759,000 after buying an additional 15,590 shares during the last quarter. Finally, Shell Asset Management Co. acquired a new stake in Sucampo Pharmaceuticals during the fourth quarter valued at approximately $1,324,000.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.